Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diasorin SpAMIL:DIA +0.47%76 3-Year EPS without NRI Growth Rate is -8.90% as of Jun. 2026. GuruFocus rates MIL:DIA with a GF Score™ of 76/100 and a GF Value™ of €99.46 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 161 Medical Diagnostics & Research companies, Diasorin SpA ranks worse than 78.26% on this metric.
During the past 12 months, Diasorin SpA's average EPS without NRI Growth Rate was -13.00% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -8.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -9.20% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Diasorin SpA was 177.80% per year. The lowest was -15.40% per year. And the median was 15.70% per year.
Diasorin SpA (MIL:DIA) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Diasorin SpA 3-Year EPS without NRI Growth Rate Related Terms
MIL:DIA vs TMO, DHR, NTRA: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's 3-Year EPS without NRI Growth Rate falls into.
Diasorin SpA 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -8.90% mean?
Diasorin SpA (MIL:DIA) has a 3-Year EPS without NRI Growth Rate of -8.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Diasorin SpA and its competitors. According to the industry distribution chart, Diasorin SpA ranks #126 out of 161 companies in the Medical Diagnostics & Research industry, placing it in the top 78.3%.
Is Diasorin SpA's 3-Year EPS without NRI Growth Rate too high?
Diasorin SpA's current 3-Year EPS without NRI Growth Rate is -8.90%. Based on the distribution chart, Diasorin SpA ranks #126 out of 161 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Diasorin SpA has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's 3-Year EPS without NRI Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #126 out of 161 companies for 3-Year EPS without NRI Growth Rate. This places Diasorin SpA in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 10.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 10.70, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current 3-Year EPS without NRI Growth Rate is -8.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €99.46, compared to a current price of €77.98 — trading 21.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -8.90%. Diasorin SpA's overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current 3-Year EPS without NRI Growth Rate is -8.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (MIL:DIA) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €77.98 is trading 21.6% below its estimated GF Value™ of €99.46.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for MIL:DIA:
3-Year EPS without NRI Growth Rate: -8.90%
GF Value™: €99.46 vs. price of €77.98 (21.6% below fair value)
No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DiaSorin SpA is an Italian in vitro diagnostics company that develops, manufactures, and markets reagent kits, instruments, and software for clinical laboratories and research institutions. Its portfolio spans immunodiagnostics, molecular diagnostics, and licensed technologies, covering infectious diseases, endocrinology, bone and mineral metabolism, oncology, and autoimmune conditions. The company also supplies diagnostic tests for food and water safety through its industrial diagnostics business. DiaSorin sells directly and through distributors across Europe, North America, and other international markets, generating revenue from instrument placements, consumable reagent sales, and licensing royalties. Its molecular diagnostics offerings include the Liaison and Simplexa platforms, while immunodiagnostics center on the Liaison family of analyzers. The company expanded its molecular portfolio through the acquisition of Luminex, adding multiplexing technology used in both clinical and life-science applications.
76GF Score
Get the complete analysis for MIL:DIA
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:DIA has been successfully added to your 
